It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The intracellular transport of cholesterol is subject to tight regulation. The structure of the lysosomal integral membrane protein type 2 (LIMP-2, also known as SCARB2) reveals a large cavity that traverses the molecule and resembles the cavity in SR-B1 that mediates lipid transfer. The detection of cholesterol within the LIMP-2 structure and the formation of cholesterol−like inclusions in LIMP-2 knockout mice suggested the possibility that LIMP2 transports cholesterol in lysosomes. We present results of molecular modeling, crosslinking studies, microscale thermophoresis and cell-based assays that support a role of LIMP-2 in cholesterol transport. We show that the cavity in the luminal domain of LIMP-2 can bind and deliver exogenous cholesterol to the lysosomal membrane and later to lipid droplets. Depletion of LIMP-2 alters SREBP-2-mediated cholesterol regulation, as well as LDL-receptor levels. Our data indicate that LIMP-2 operates in parallel with Niemann Pick (NPC)-proteins, mediating a slower mode of lysosomal cholesterol export.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 Biochemisches Institut, Christian-Albrechts-Universität Kiel, Kiel, Germany
2 Faculty of Medicine, Anatomy and Stem Cells and Metabolism Research Program, University of Helsinki, Helsinki, Finland; Minerva Foundation Institute for Medical Research, Helsinki, Finland
3 Department of Cell Biology, and Department of Pathology Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P.R. China
4 Program in Molecular Medicine, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada; Department of Biochemistry, University of Toronto, Toronto, Canada
5 Department of Biochemistry, University of Toronto, Toronto, Canada
6 Department of Chemistry and Biochemistry, Queens College, City University of New York, Flushing, New York, USA
7 Cell Biology Program, Hospital for Sick Children, Toronto, Canada
8 Department of Biochemistry, University of Toronto, Toronto, Canada; Cell Biology Program, Hospital for Sick Children, Toronto, Canada; Department of Physiology, University of Toronto, Toronto, Canada
9 Department of Biochemistry, University of Toronto, Toronto, Canada; Princes Margaret Cancer Centre, Toronto, ON, Canada
10 Laboratory for Membrane Trafficking, VIB-Center for Brain and Disease Research, Leuven, Belgium
11 Faculty of Chemistry, Biochemistry III, University of Bielefeld, Bielefeld, Germany; Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
12 Institut für Biochemie und Molekulare Zellbiologie, Zentrum für Experimentelle Medizin, Universitätsklinikum Hamburg-Eppendorf, Hamburg-Eppendorf, Germany
13 Institut für Anatomie, Christian-Albrechts-Universität Kiel, Kiel, Germany
14 Department of Biochemistry, University of Toronto, Toronto, Canada; Cell Biology Program, Hospital for Sick Children, Toronto, Canada